Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, PO Box 9510, Morgantown, WV, 26506-9510, USA.
Health Policy, Management, and Leadership Department, School of Public Health, West Virginia University, Morgantown, WV, USA.
Pharmacoeconomics. 2021 Jun;39(6):639-651. doi: 10.1007/s40273-021-01029-2. Epub 2021 Apr 27.
Major depressive disorder (MDD) and chronic non-cancer pain conditions (CNPC) often co-occur and exacerbate one another. Treatment-resistant depression (TRD) in adults with CNPC can amplify the economic burden. This study examined the impact of TRD on direct total and MDD-related healthcare resource utilization (HRU) and costs among commercially insured patients with CNPC and MDD in the US.
The retrospective longitudinal cohort study employed a claims-based algorithm to identify adults with TRD from a US claims database (January 2007 to June 2017). Costs (2018 US$) and HRU were compared between patients with and without TRD over a 12-month period after TRD/non-TRD index date. Counterfactual recycled predictions from generalized linear models were used to examine associations between TRD and annual HRU and costs. Post-regression linear decomposition identified differences in patient-level factors between TRD and non-TRD groups that contributed to the excess economic burden of TRD.
Of the 21,180 adults with CNPC and MDD, 10.1% were identified as having TRD. TRD patients had significantly higher HRU, translating into higher average total costs (US$21,015 vs US$14,712) and MDD-related costs (US$1201 vs US$471) compared with non-TRD patients (all p < 0.001). Prescription drug costs accounted for 37.6% and inpatient services for 30.7% of the excess total healthcare costs among TRD patients. TRD patients had a significantly higher number of inpatient (incidence rate ratio [IRR] 1.30, 95% CI 1.14-1.47) and emergency room visits (IRR 1.21, 95% CI 1.10-1.34) than non-TRD patients. Overall, 46% of the excess total costs were explained by differences in patient-level characteristics such as polypharmacy, number of CNPC, anxiety, sleep, and substance use disorders between the TRD and non-TRD groups.
TRD poses a substantial direct economic burden for adults with CNPC and MDD. Excess healthcare costs may potentially be reduced by providing timely interventions for several modifiable risk factors.
重度抑郁症(MDD)和慢性非癌性疼痛疾病(CNPC)常同时发生并相互加重。成人慢性非癌性疼痛伴治疗抵抗性抑郁症(TRD)会放大经济负担。本研究旨在考察美国慢性非癌性疼痛伴 MDD 成人中 TRD 对直接总费用和与 MDD 相关的医疗资源利用(HRU)的影响。
本回顾性纵向队列研究采用索赔算法,从美国索赔数据库(2007 年 1 月至 2017 年 6 月)中识别出 TRD 成人。在 TRD/非 TRD 索引日期后 12 个月内,比较 TRD 患者和无 TRD 患者的直接总费用和与 MDD 相关的 HRU。使用广义线性模型的反事实再预测来检验 TRD 与年度 HRU 和费用之间的相关性。回归后线性分解确定了 TRD 组和非 TRD 组患者之间导致 TRD 经济负担过高的差异因素。
在 21180 名患有慢性非癌性疼痛和 MDD 的成年人中,有 10.1%被确定为患有 TRD。TRD 患者的 HRU 显著更高,导致平均总费用(21015 美元比 14712 美元)和与 MDD 相关的费用(1201 美元比 471 美元)显著高于非 TRD 患者(均 P<0.001)。处方药费用占 TRD 患者总医疗保健费用超支的 37.6%,住院服务占 30.7%。与非 TRD 患者相比,TRD 患者的住院(发病率比 [IRR]1.30,95%CI1.14-1.47)和急诊就诊(IRR1.21,95%CI1.10-1.34)次数明显更多。总体而言,TRD 组和非 TRD 组患者在多药治疗、慢性非癌性疼痛次数、焦虑、睡眠和物质使用障碍等方面的差异导致了 46%的总费用超支。
TRD 给患有慢性非癌性疼痛和 MDD 的成年人带来了巨大的直接经济负担。通过及时干预一些可改变的风险因素,可能会降低过度的医疗保健费用。